scholarly journals Molecular-targeted therapy hypoxia in head and neck squamous cell carcinoma patients

2012 ◽  
Vol 1 (1) ◽  
pp. 12-14
Author(s):  
MAKOTO ADACHI ◽  
LIGY THOMAS
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Molecular Targeted Therapy ◽  
Neck Squamous Cell Carcinoma

scholarly journals Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

2019 ◽  
Vol 3 (4) ◽  
Author(s):  
Paul Gougis ◽  
Camille Moreau Bachelard ◽  
Maud Kamal ◽  
Hui K Gan ◽  
Edith Borcoman ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cancer Biology ◽  
Molecular Targeted Therapy ◽  
Locally Advanced ◽  
Clinical Development ◽  
Neck Squamous Cell Carcinoma

Abstract A better understanding of cancer biology has led to the development of molecular targeted therapy, which has dramatically improved the outcome of some cancer patients, especially when a biomarker of efficacy has been used for patients’ selection. In head and neck oncology, cetuximab that targets epidermal growth factor receptor is the only targeted therapy that demonstrated a survival benefit, both in the recurrent and in the locally advanced settings, yet without prior patients’ selection. We herein review the clinical development of targeted therapy in head and neck squamous cell carcinoma in light of the molecular landscape and give insights in on how innovative clinical trial designs may speed up biomarker discovery and deployment of new molecular targeted therapies. Given the recent approval of immune checkpoint inhibitors targeting programmed cell death-1 in head and neck squamous cell carcinoma, it remains to be determined how targeted therapy will be incorporated into a global drug development strategy that will inevitably incorporate immunotherapy.

Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, Their Niche and Targeted Therapy

2020 ◽  
Vol 15 ◽  
Author(s):  
Meriç Bilgiç Küçükgüven ◽  
Betül Çelebi-Saltik
Keyword(s):  
Stem Cells ◽  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cancer Stem Cells ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Crucial Role ◽  
Tumor Therapy ◽  
Neck Squamous Cell Carcinoma

: Head and Neck Squamous Cell Carcinoma (HNSCC) is categorized as the sixth most common cancer worldwide, with an incidence of more than 830,000 cases per year and a mortality rate of 50%. Tobacco use, alcohol consumption, and Human Papillomavirus infection are the prominent risks for HNSCC. Despite significant developments in the treatment of HNSCC, a high rate of recurrences makes the clinical situation worse and results in poor survival rates. Recent perspectives demonstrate that whereas epithelial transformation plays a crucial role in cancer development, tumor surrounding microenvironment takes part in progression of cancer as well. Cancer Stem Cells (CSCs), which harbor unlimited self-renewal capacity, have a crucial role in the growth of HNSCC and this cell population is responsible for tumor recurrence unless eliminated by targeted therapy. CSCs are not only a promising target for tumor therapy, but also a crucial biomarker to determine the patients at high risk for undetermined results and disease development. Just as the bone marrow which is the niche of hematopoietic and mesenchymal stem cells, is important for stem cells maintenance. Similarly, the concept of microenvironment is also important for the maintenance of CSCs. Apart from the cell-cell interactions, there are many parameters in the cancer microenvironment that affect the development of cancer, such as extracellular regulation, vascularization, microbial flora, pH and oxygenation. The purpose of this review is to introduce HNSCC, explain the role of CSCs and their microenvironment and refer to the conventional and novel targeted therapy for HNSCC and CSCs.

scholarly journals 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma

2016 ◽  
Vol 23 (10) ◽  
pp. 2516-2527 ◽  
Author(s):  
Samuel A. Kerk ◽  
Kelsey A. Finkel ◽  
Alexander T. Pearson ◽  
Kristy A. Warner ◽  
Zhaocheng Zhang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cancer Stem Cells ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma

scholarly journals Impact of gene polymorphisms on toxicity and response rate in head and neck squamous cell carcinoma: a literature review

2022 ◽  
Author(s):  
hamid abbaszadeh ◽  
Mahdieh Rajabi-Moghaddam
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Gene Polymorphisms ◽  
Response To Therapy ◽  
Neck Squamous Cell Carcinoma ◽  
Response To Treatment ◽  
The Impact

Abstract Advanced head and neck squamous cell carcinoma (HNSCC) is treated with radiotherapy, chemotherapy, targeted therapy or a combination of these treatments. Variations in toxicity and response to therapy are observed among patients despite similar clinicopathologic characteristics which are attributed to single nucleotide polymorphisms (SNPs). The aim of this review was to evaluate the impact of SNPs on toxicity and response to therapy in HNSCCs. A web-based search of all original articles about the impact of gene polymorphisms on toxicity and response to therapy in HNSCCs was done until September 2021 using international English language databases including Google Scholar, Scopus, PubMed and Web of science. Findings were categorized by type of treatment (radiotherapy, chemotherapy, targeted therapy, or combination therapy). In each category, studies related to growth control genes, cell proliferation, apoptosis, DNA repair genes, antioxidant and drug detoxification genes, genes of drug metabolizing enzymes, tissue remodeling genes and genes of antibody-dependent cellular cytotoxicity were discussed separately. Among studied SNPs with probable impact on toxicity and response to therapy are XRCC1, XRCC3, RAD51, Ku70, NBN, CAT, GSTP1, GSTT1, GSTM1, XPD, XPC, ERCC1, MMP3, ACSL6, EXO1, CXP2D6, FcγRIIIa, AurkA, and EGFR. Understanding gene polymorphisms will help us move toward personalized medicine and determine which patients will actually benefit from therapies for HNSCCs. By examining the SNPs, it is possible to make predictions about the patient's response to treatment or development of toxicity after treatment, and if necessary, make changes in the patient's treatment regimen.

Sign in / Sign up

Export Citation Format

Share Document